Finance

Lists
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
2 268,40 ₹
+1,00%
(+22,40) 1D
15 հոկ, 13:58:03 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
2 242,00 ₹
High
2 289,50 ₹
Low
2 241,20 ₹
Mkt. cap
639,44 մլրդ
Avg. vol.
554,25 հզր
Volume
352,14 հզր
Dividend
0,22%
Quarterly dividend
1,25 ₹
Ex-dividend date
03 հոկ, 2025 թ.
P/E ratio
35,62
52-wk high
2 537,60 ₹
52-wk low
1 792,60 ₹
EPS
63,68 ₹
Shares outstanding
0,00
No. of employees
17 հզր
Open
2 242,00 ₹
High
2 289,50 ₹
Low
2 241,20 ₹
Mkt. cap
639,44 մլրդ
Avg. vol.
554,25 հզր
Volume
352,14 հզր
Dividend
0,22%
Quarterly dividend
1,25 ₹
Ex-dividend date
03 հոկ, 2025 թ.
P/E ratio
35,62
52-wk high
2 537,60 ₹
52-wk low
1 792,60 ₹
EPS
63,68 ₹
Shares outstanding
0,00
No. of employees
17 հզր
News stories
From web sources and news partners
Profile
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees16,9 հզր
Founded1977
Headquarters-
Sector-
Last report
03 օգս, 2026 թ.
Fiscal period
Q1 2027
17,11 ₹ / 17,30 ₹
-1,10%miss
Revenue / Est. (INR)
40,18 մլրդ / 39,17 մլրդ
+2,60%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
60,47 մլրդ
39,01 մլրդ
38,31 մլրդ
40,18 մլրդ
Cost of goods sold
12,65 մլրդ
12,95 մլրդ
13,65 մլրդ
12,46 մլրդ
Cost of revenue
12,65 մլրդ
12,95 մլրդ
13,65 մլրդ
12,46 մլրդ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,86 մլրդ
8,41 մլրդ
16,49 մլրդ
9,35 մլրդ
Operating expense
25,64 մլրդ
18,90 մլրդ
17,91 մլրդ
21,41 մլրդ
Total operating expenses
38,29 մլրդ
31,85 մլրդ
31,56 մլրդ
33,87 մլրդ
Operating income
22,18 մլրդ
7,15 մլրդ
6,75 մլրդ
6,32 մլրդ
Other non operating income
2,01 մլրդ
444,65 մլն
-2,72 մլրդ
657,64 մլն
EBT including unusual items
9,67 մլրդ
5,34 մլրդ
3,88 մլրդ
6,43 մլրդ
EBT excluding unusual items
23,53 մլրդ
7,18 մլրդ
7,61 մլրդ
6,43 մլրդ
Income tax expense
3,57 մլրդ
1,31 մլրդ
864,49 մլն
1,61 մլրդ
Effective tax rate
36,90%
24,49%
22,29%
24,96%
Other operating expenses
13,37 մլրդ
8,94 մլրդ
-55,65 մլն
10,33 մլրդ
Net income
6,10 մլրդ
4,03 մլրդ
3,01 մլրդ
4,83 մլրդ
Net profit margin
10,09%
10,34%
7,87%
12,02%
Earnings per share
-
19,21
20,96
17,11
Interest and investment income
-
-
413,36 մլն
-
Interest expense
-664,63 մլն
-414,32 մլն
-426,04 մլն
-539,97 մլն
Net interest expenses
-664,63 մլն
-414,32 մլն
-12,68 մլն
-539,97 մլն
Depreciation and amortization charges
1,41 մլրդ
1,54 մլրդ
1,48 մլրդ
1,73 մլրդ
EBITDA
23,54 մլրդ
7,80 մլրդ
7,80 մլրդ
7,75 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps